Guidelines for the programmatic management of drug-resistant tuberculosis : emergency update 2008 /

"The emergence of extensively drug-resistant strains of tuberculosis, especially in countries with a high prevalence of human immunodeficiency virus, is a serious threat to global public health and jeopardizes efforts to effectively control the disease. This publication offers updated recommend...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autores Corporativos: Stop TB Initiative (World Health Organization), Great Britain. Department for International Development, United States. Agency for International Development
Otros Autores: Jaramillo, Ernesto
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Geneva : World Health Organization, Stop TB Dept., ©2008.
Edición:Emergency update.
Temas:
Multidrug-resistant tuberculosis > Chemotherapy.
Multidrug-resistant tuberculosis > Prevention.
Antitubercular agents.
HIV infections > Chemotherapy.
Comorbidity > Treatment.
Highly active antiretroviral therapy.
Tuberculosis, Multidrug-Restant > drug therapy
Tuberculosis, Multidrug-Restant > prevention & control
Antitubercular Agents > administration & dosage
HIV Infections > drug therapy
Antiretroviral Therapy, Highly Active
Tuberculose multirésistante > Chimiothérapie.
Antituberculeux.
Infections à VIH > Chimiothérapie.
Comorbidité > Traitement.
Traitement antirétroviral hautement actif.
MEDICAL > Oncology.
Antitubercular agents
Highly active antiretroviral therapy
HIV infections > Chemotherapy
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Background information on DR-TB
  • Framework for effective control of DR-TB
  • Political commitment and coordination
  • Definitions : case registration, bacteriology and treatment outcomes
  • Case-finding strategies
  • Laboratory aspects
  • Treatment strategies for MDR-TB and XDR-TB
  • Mono-resistant and poly-resistant strains
  • Treatment of DR-TB in special conditions and situations
  • DR-TB and HIV infection
  • Initial evaluation, monitoring of treatment and management of adverse effects
  • Treatment delivery and community-based DR-TB support
  • Management of patients after MDR-TB treatment failure
  • Management of contacts of MDR-TB patients
  • Drug resistance and infection control
  • Human resources : training and staffing
  • Management of second-line antituberulosis drugs
  • Category IV recording and reporting system
  • Managing DR-TB through patient-centred care
  • Appendices.

Ejemplares similares